Evidence for Early Impairment of Glucagon-Like Peptide 1-Induced Insulin Secretion in Human Type 2 (Non Insulin-Dependent) Diabetes
The DOI matches its Crossref record.
Abstract
UNLABELLED: To investigate a possible role of an enteroinsular axis involvement in the pathogenesis of type 2 diabetes, plasma glucagon-like peptide 1 (GLP-1) 7-36 amide response to nutrient ingestion was evaluated in type 2 diabetics affected by different degrees of beta-cell dysfunction. METHODS: 14 patients on oral hypoglycaemic treatment (group A: HbA1C = 8.1 +/- 1.8 %) and 11 age-matched diabetic patients on diet only (group B: HbA1C = 6.4 +/- 0.9) participated in the study. 10 healthy volunteers were studied as controls. In the postabsorptive state, a mixed meal (700 kCal) was administered to all subjects, and blood samples were regularly collected up to 180' for plasma glucose, insulin, glucagon, and GLP-1 determination. RESULTS: In the control group, the test meal induced a significant increase in plasma GLP-1 at 30' and 60' (p < 0.01); the peptide concentrations then returning toward basal levels. beta-cell function estimation by HOMA score confirmed a more advanced involvement in group A than in group B (p < 0.01). In contrast, the insulin resistance degree showed a similar result in the two groups (HOMA-R). In group A, first-phase postprandial insulin secretion (0 - 60') resulted, as expected, in being significantly reduced compared to healthy subjects (p < 0.001). In the same patients the mean fasting GLP-1 value was similar to controls, but the meal failed to increase plasma peptide levels, which even tended to decrease during the test (p < 0.01). In group B, food-mediated early insulin secretion was higher than in group A (p < 0.001), although significantly reduced when compared to controls (p < 0.01). Like group A, no GLP-1 response to food ingestion occurred in group B patients in spite of maintained basal peptide secretion. Whereas the test-meal did not significantly modify plasma glucagon levels in the control group, glucagon concentrations increased at 30' and 60' in both diabetic groups (p < 0.01). CONCLUSIONS: 1) The functional integrity of GLP-1 cells results as being seriously impaired even in the condition of mild diabetes; 2) the early peptide failure could contribute to the development of beta-cell deterioration which characterizes overt type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Glucose Metabolism and Regulation: Beyond Insulin and Glucagon
Aronoff, S. L., Berkowitz, K., Shreiner, B., & Want, L. (2004) · Diabetes Spectrum · doi:10.2337/diaspect.17.3.183 · Cited by 569
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
“(30) reported that, even after ingestion of 700 kcal, a GLP-1 response could not be detected in type 2 diabetic patients.”
BackgroundResultSecretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
“Against this background, reports that GLP-1 secretion from L-cells is reduced in patients with type 2 diabetes [10, 11] have prompted several hypotheses about how this affects the estimated clinical effectiveness of these novel drugs.”
BackgroundUpregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes
Hennige, A. M., Burks, D. J., Ozcan, U., Kulkarni, R. N., Ye, J., Park, S., Schubert, M., Fisher, T. L., Dow, M. A., Leshan, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18581 · Cited by 262
Moriya, R., Shirakura, T., Ito, J., Mashiko, S., & Seo, T. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00412.2009 · Cited by 156
“Because patients with type 2 diabetes have lower postprandial incretin levels (10, 18, 21), a therapeutic strategy that has been receiving increasing interest involves the use of oral drugs that increase circulating bioactive GIP and GLP-1 levels to stimulate secretion of endogenous incretin from intestinal K and L ce…”
BackgroundAsahara, S., Shibutani, Y., Teruyama, K., Inoue, H. Y., Kawada, Y., Etoh, H., Matsuda, T., Kimura-Koyanagi, M., Hashimoto, N., Sakahara, M., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2849-5 · Cited by 103
Metadata
- Authors
- Lugari, R., Dei Cas, A., Ugolotti, D., Finardi, L., Barilli, A., Ognibene, C., Luciani, A., Zandomeneghi, R., & Gnudi, A.
- Venue
- Hormone and Metabolic Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 2002-03
- Volume
- 34
- Issue
- 03
- Pages
- 150-154
- ISSN
- 0018-5043 (ISSN-L)
- 1439-4286
- OpenAlex
- W2069375870
- Cited by
- 84
- References
- 0
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.